Minerva Neurosciences Inc
Fermé
4.39 5.78
Résumé
Variation du prix de l'action
24h
Min
4.18
Max
4.58
Revenu | 158M -125M |
|---|---|
P/E Moyenne du Secteur | 2.462 49.712 |
BPA | -0.36 |
Employés | 7 |
Recommandations | Achat |
|---|---|
Prévisions sur 12 Mois | +134.9% upside |
Prochains Résultats | 12 août 2026 |
|---|
Capitalisation Boursière | -13M 172M |
|---|---|
Ouverture précédente | -1.39 |
Clôture précédente | 4.39 |
Minerva Neurosciences Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
